Australia approves first GLP-1 weight loss pill Foundayo
Summarised from 2 outlets · Updated 17 Nov, 00:43 · Archive
Australia's Therapeutic Goods Administration has approved Foundayo, a daily GLP-1 pill for weight loss and type 2 diabetes treatment. Made by US pharmaceutical company Lilly, it is the first-of-its-kind GLP-1 pill that can be taken at any time of day without food or water restrictions. The drug works by targeting and simulating a natural hormone in the body to control hunger and slow digestion, similar to injectable drugs such as Ozempic and Wegovy.
Clinical trials of Foundayo involved more than 10,000 patients in 15 countries, including partnerships with a dozen Australian hospitals and clinics. The drug is now available through private prescription but has not yet been added to the Pharmaceutical Benefits Scheme, Australia's subsidised medicines programme.
Samantha Hocking, President of the National Association of Clinical Obesity Services, said the approval could help address obesity in Australia. She noted that around 13 million Australian adults are overweight or obese, and that obesity increases the risk of at least 30 serious medical conditions including cancer, cardiovascular disease and type 2 diabetes. Lilly Australia said its focus is on delivering broader access for Australians who may benefit from the medicine.

How it is being reported
- TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian useClinical trials involved more than 10,000 patients in 15 countries.Perth Now · 17 Nov, 00:20
- TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian useClinical trials involved more than 10,000 patients in 15 countries.The West Australian · 17 Nov, 00:19
In this story: Australia · Therapeutic Goods Administration · Foundayo · Lilly · Samantha Hocking · Manny Simons
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)